Product Code: BH043A
The regenerative medicines market generated $17.03 billion revenue in 2016. The North America regenerative medicines market currently holds 39% percent of the global regenerative medicines market. Technological innovations across the various segments of the regenerative medicine have propelled growth in the recent past in the region.
Due to the fall of the fertility rates, and increased life expectancy, the world population is ageing rapidly. The prevalence of diseases such as diabetes, osteoarthritis, cardiovascular diseases, Alzheimer's, and many others, are higher among the elderly. As per the Arthritis Foundation, the older population in the U.S. affected by arthritis is estimated to grow to 21% by 2040, from the current value of 15%. The rising prevalence of chronic diseases is another factor contributing to the growth of the market. In the recent years, the prevalence of chronic diseases has been increasing irrespective of the age. As per WHO, the global prevalence of diabetes increased to 8.5% in adults over the age of 18 years in 2014 from 4.7% in 1980. The prevalence of genetic diseases, and cancer has also witnessed a rise in the recent years.
Regenerative medicine presents with opportunities to change the treatment options, and offers complete cure of the diseases. The pharmaceutical industry is witnessing the growth of pipeline of candidates for regenerative medicine. A number of companies are now indulging in the research and development of such therapies.
The regenerative medicine market includes various cellular, and acellular products. The market involves various therapies such as gene therapy, cell therapy, and tissue engineering. This therapy is being applied to a number of diseases, and therapeutic areas such as orthopaedic, cardiovascular, wound healing, diabetes, neurodegenerative, immune-oncology, and others. The market analysis includes an in-depth examination of the key ecosystem players, and the key strategies and developments taking place in this market. Additionally, it includes market dynamics (market drivers, opportunities, and challenges), and industry analysis.
The purpose of the study is to gain a holistic view of the regenerative medicine market in terms of various factors influencing it such as recent trends, technological advancements, and regulatory aspects of the market. The scope of this report is centred upon conducting a detailed study of the solutions allied with the regenerative medicine market. The market has been segmented into ‘product', ‘therapy', ‘application', and ‘geographical regions'. The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market, and helps in forming well informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into the consideration before entering the market.
This research report aims at answering various aspects of the global regenerative medicine market with the help of the key factors driving the market, threats that can possibly inhibit the overall market growth, and the current growth opportunities that are going to shape the future trajectory of the market expansion. The study considers the growth-share matrix model for a comprehensive study of the global regenerative medicine market, and assesses the factors governing the same.
The answers to the following key questions can be derived from this report:
- What are the major market drivers, challenges, and opportunities in the global regenerative medicine market?
- How did the regenerative medicine market evolve, and what is its scope in the future?
- What is the market share of the leading segments, and sub-segments of the global regenerative medicine market in 2017 and 2025?
- How will each segment of the global regenerative medicine market grow during the forecast period, and what will be the revenue generated by each of the segments by the end of 2025?
- What are the influencing factors that may affect the market share of the key players?
- How will the industry evolve during the forecast period 2017-2025?
- What are the key developmental strategies implemented by the key players to stand out in this market?
- What will be the growth rate of the tissue engineering segment during the forecast period?
- Which therapy segment is expected to register the highest CAGR for the regenerative medicine market?
- How has the market been segmented on the basis of application? Which application segment has the largest share, and growth rate in the regenerative medicine market?
- What will be the value of immune-oncology segment by 2025?
- Which geographical location will contribute to the highest sales of regenerative medicine?
The key players that have been contributing significantly to the regenerative medicine market are Novartis AG, ViaCyte, Inc., Vericel Corporation, Tissue Regenix, Osiris Therapeutics, Inc., NuVasive, Inc., MiMedx Group Inc., Mesoblast Limited, Acelity, and Cytori Therapeutics, among others.
Table of Contents
Executive Summary
1. Report Scope
- 1.1. Scope of the Report
- 1.2. Global Regenerative Medicine Market Segmentation
- 1.3. Research Methodology
- 1.3.1. Data Triangulation
- 1.3.2. Key Data Points From Secondary Sources
- 1.3.3. Key Data Points From Primary Sources
- 1.3.4. Top-Down Approach (Segmental Analysis)
- 1.3.5. Bottom-Up Approach (Segmental Analysis)
- 1.3.6. Assumptions and Limitations
- 1.3.7. Data and Prediction Modelling
2. Market Overview
- 2.1. Introduction
- 2.2. Evolutionary History
- 2.3. Present And Future
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Challenges
- 3.3. Market Opportunities
4. Competitive Landscape
- 4.1. Share of Key Developments & Strategies
- 4.2. Market Share Analysis
- 4.3. Porter's Five Force Analysis
5. Global Regenerative Medicines Market, by Therapy
- 5.1. Cell Therapy
- 5.2. Gene Therapy
- 5.3. Tissue Engineering
6. Global Regenerative Medicines Market, by Product (Qualitative)
- 6.1. Introduction
- 6.2. . Acellular Products
- 6.3. Cellular Products
- 6.4. Products
- 6.5. Pipeline Products
7. Global Regenerative Medicines Market, by Application
- 7.1. Introduction
- 7.2. Orthopaedic & Dental
- 7.3. Cardiology
- 7.4. Wound Healing
- 7.5. Diabetes
- 7.6. Immuno-Oncology
- 7.7. Others
8. Global Regenerative Medicines Market, by Region
- 8.1. Introduction
- 8.2. North America
- 8.3. Europe
- 8.4. Asia Pacific
- 8.5. Rest of the World
9. Company Profiles
- 9.1. Acelity
- 9.1.1. Overview
- 9.1.2. Product Portfolio
- 9.1.3. Financials
- 9.1.3.1. Financial Summary
- 9.1.4. Acelity: SWOT Analysis
- 9.2. Athersys, Inc.
- 9.2.1. Overview
- 9.2.2. Product Pipeline
- 9.2.3. Financials
- 9.2.3.1. Financial Summary
- 9.2.4. Athersys, Inc.: SWOT Analysis
- 9.3. . Cellular Biomedicine Group, Inc.
- 9.3.1. Overview
- 9.3.2. Product Pipeline
- 9.3.3. Financials
- 9.3.4. Cellular Biomedicine Group, Inc.: SWOT Analysis
- 9.4. . Cytori Therapeutics
- 9.4.1. Overview
- 9.4.2. Product Portfolio
- 9.4.3. Financials
- 9.4.3.1. Financial Summary
- 9.4.4. Cytori Therapeutics: SWOT Analysis
- 9.5. Integra Lifesciences Corporation
- 9.5.1. Overview
- 9.5.2. Product Portfolio
- 9.5.3. Financials
- 9.5.3.1. Financial Summary
- 9.5.4. Integra Lifesciences Corporation: SWOT Analysis
- 9.6. Mesoblast Limited
- 9.6.1. Overview
- 9.6.2. Product Portfolio
- 9.6.3. Financials
- 9.6.3.1. Financial Summary
- 9.6.4. Mesoblast Limited: SWOT Analysis
- 9.7. MiMedx Group Inc.
- 9.7.1. Overview
- 9.7.2. Product Portfolio
- 9.7.3. Financials
- 9.7.3.1. Financial Summary
- 9.7.4. MiMedx Group Inc.: SWOT Analysis
- 9.8. Novartis International AG
- 9.8.1. Overview
- 9.8.2. Product Portfolio
- 9.8.3. Financials
- 9.8.3.1. Financial Summary
- 9.8.4. Novartis International AG: SWOT Analysis
- 9.9. NuVasive, Inc.
- 9.9.1. Overview
- 9.9.2. Product Portfolio
- 9.9.3. Financials
- 9.9.3.1. Financial Summary
- 9.9.4. Nuvasive, Inc: SWOT Analysis
- 9.10. Organogenesis Inc.
- 9.10.1. Overview
- 9.10.2. Product Portfolio
- 9.10.3. Corporate Summary
- 9.10.4. Organogenesis Inc.: SWOT Analysis
- 9.11. OSIRIS THERAPEUTICS, INC.
- 9.11.1. Overview
- 9.11.2. Product Portfolio
- 9.11.3. Financials
- 9.11.3.1. Financial Summary
- 9.11.4. OSIRIS THERAPEUTICS, INC.: SWOT Analysis
- 9.12. STRYKER CORPORATION
- 9.12.1. Overview
- 9.12.2. Product Portfolio
- 9.12.3. Financials
- 9.12.3.1. Financial Summary
- 9.12.4. STRYKER CORPORATION: SWOT Analysis
- 9.13. TERUMO CORPORATION
- 9.13.1. Overview
- 9.13.2. Product Portfolio
- 9.13.3. Financials
- 9.13.3.1. Financial Summary
- 9.13.4. TERUMO CORPORATION: SWOT Analysis
- 9.14. TiGenix
- 9.14.1. Overview
- 9.14.2. Product Pipeline
- 9.14.3. Financials
- 9.14.3.1. Financial Summary
- 9.14.4. TiGenix: SWOT Analysis
- 9.15. Tissue Regenix
- 9.15.1. Overview
- 9.15.2. Product Portfolio & Product Pipeline
- 9.15.3. Financials
- 9.15.3.1. Financial Summary
- 9.15.4. Tissue Regenix: SWOT Analysis
- 9.16. Vericel Corporation
- 9.16.1. Overview
- 9.16.2. Product Portfolio
- 9.16.3. Financials
- 9.16.3.1. Financial Summary
- 9.16.4. Vericel Corporation: SWOT Analysis
- 9.17. ViaCyte, Inc.
- 9.17.1. Overview
- 9.17.2. Product Pipeline
- 9.17.3. Corporate Summary
- 9.17.4. ViaCyte, Inc.: SWOT Analysis
- 9.18. Zimmer Biomet Holdings Inc
- 9.18.1. Overview
- 9.18.2. Product Portfolio
- 9.18.3. Financials
- 9.18.3.1. Financial Summary
- 9.18.4. Zimmer Biomet Holdings Inc: SWOT Analysis
- 9.19. Anika Therapeutics
- 9.20. Capricor Therapeutics
- 9.21. COOK BIOTECH, INC.
- 9.22. Gamida Cell
- 9.23. Juno Therapeutics
